Hospitals Segment to Lead Europe Intra-Articular Injection for Osteoarticular Infiltrations Market During 2023–2031

According to our new research study on “Europe Intra-Articular Injection for Osteoarticular Infiltrations Market Forecast to 2031 – Regional Analysis – by Type, End User, and Country,” the market is expected to grow from US$ 97.43 million in 2023 to US$ 157.08 million by 2031; it is estimated to record a CAGR of 6.2% from 2023–2031. Osteoarticular disorders include osteoarthritis, rheumatoid arthritis, osteoporosis, lupus arthritis, psoriatic arthritis, and other such diseases. Osteoarticular and muscular disorders restrict mobility and dexterity, resulting in an early decline of activity, decreased well-being, and often a decrease in the ability to participate in society. Intra-articular injections for osteoarthritis are a medical procedure where medication is injected directly into a joint affected by osteoarthritis. This approach is intended to reduce pain and improve joint function. Intra-articular injections are typically used when conservative treatments (such as oral medications, physical therapy, and lifestyle modifications) have not provided sufficient relief for osteoarthritis symptoms. They can be particularly effective for patients with localized pain in specific joints, such as the knee, hip, or shoulder. Intra-articular injections can be an effective component of the management strategy for osteoarthritis, particularly for patients with moderate to severe joint pain. Key factors driving the Europe intra-articular injection for osteoarticular infiltrations market growth are the increasing prevalence of osteoarthritis and advancements in injection techniques. However, the side effects associated with intra-articular injections hinder the market's growth. The increasing prevalence of osteoarthritis among the aging population, the growing need for effective treatments, and increased awareness among healthcare professionals and patients regarding the benefits of collagen injections have propelled the demand for intra-articular injections, thereby favoring the Europe intra-articular injection for osteoarticular infiltrations market growth.

Based on type, the Europe intra-articular injection for osteoarticular infiltrations market is bifurcated into Type 1 collagen and hyaluronic acid. Based on end user, the market is categorized into hospitals, orthopedic clinics, and others.

Based on end user, the Europe intra-articular injection for osteoarticular infiltrations market is segmented into hospitals, orthopedic clinics, and others. The hospitals segment held the largest Europe intra-articular injection for osteoarticular infiltrations market share in 2023. Hospitals provide healthcare services to people through specialized scientific equipment. These facilities are classified into general, specialty, or government organizations. The increasing number of hospital admissions due to the rising incidence of osteoarthritis is projected to drive the growth of the hospital segment in the market during the forecast period. Hospitals offer cutting-edge medical infrastructure and tools, which are crucial for safely and effectively providing viscosupplementation injections. Hospitals are ideal locations for viscosupplementation procedures since these professionals are skilled in diagnosing and treating joint-related problems. Hospitals serve a significant role by providing medical services to patients suffering from osteoarticular diseases. As per ArthroSave, over 2.2 million patients are affected by knee osteoarthritis in Europe, and prevalence is rising dramatically due to rising obesity rates and the aging population.

Moreover, intra-articular injections are less invasive, have shorter recovery times, and pose lower risks than surgical interventions, making them more attractive for patients and preferable to healthcare providers. Compared to surgical alternatives, intra-articular injections are more economical options for healthcare systems, leading to increased utilization. Medicare and most insurance companies also cover viscosupplementation.

In addition, the orthopedic clinics segment is expected to register the highest CAGR from 2023 to 2031. Orthopedic clinics specialize in diagnosing, treating, and managing musculoskeletal disorders, including injuries and conditions affecting bones, joints, and muscles. They often provide a range of services, such as consultation, nonsurgical treatments (offering injections, such as hyaluronic acid), rehabilitation, and preventive care. These clinics typically employ orthopedic surgeons, physical therapists, and other healthcare professionals to provide comprehensive care. In June 2023, the Glasgow Private Clinic became Scotland's first clinic to offer a novel injectable to patients suffering from knee osteoarthritis. The clinic is a pioneer in leading the non-biodegradable injectable implant that provides safe and long-term pain relief, making it a viable alternative to invasive open knee surgery. Scottish patients suffering from pain and discomfort caused by knee osteoarthritis have the opportunity to try Arthrosamid, a novel type of hydrogel injection. Thus, the factors mentioned above support the Europe intra-articular injection for osteoarticular infiltrations market growth.

Europe Intra-Articular Injection for Osteoarticular Infiltrations Market Share Analysis by Country

The scope of the Europe intra-articular injection for osteoarticular infiltrations market report is mainly divided into Germany, the UK, France, Italy, Spain, Denmark, and the Rest of Europe. The UK held a significant share of the market in 2023. The intra-articular injection for osteoarticular infiltrations market in the UK is anticipated to grow significantly due to the growing prevalence of osteoarthritis. As per the Versus Arthritis Report “The State of Musculoskeletal Health 2024,” in the UK, 10 million people are suffering from arthritis. Out of this, 5.4 million people have knee osteoarthritis, and 3.2 million people have hip osteoarthritis. ~350,000 people are diagnosed with osteoarthritis in the nation annually. Osteoarthritis is the most common form of arthritis, affecting around one-third of the population aged 45 and more. According to the National Health Service, osteoarthritis and rheumatoid arthritis currently cost the NHS and healthcare system US$ 12.42 billion, with expenses anticipated to rise to US$ 144.43 billion over the next 10 years.

The introduction of a new hydrogel injection for knee osteoarthritis provides patients with an opportunity to return to mobility without undergoing surgery. Arthrosamid was officially introduced to the UK market during the British Orthopaedic Association Annual Congress held in September 2021. Developed by Contura International Ltd, Arthrosamid addresses an unmet clinical need for a treatment that is both effective and safe; it has a long-lasting effect and is minimally invasive aimed at reducing pain caused by knee osteoarthritis. This treatment could revolutionize the approach to managing osteoarthritis, as existing treatments involve invasive knee replacement surgery or are not very effective in the long run. In June 2023, the Glasgow Private Clinic was the first in Scotland to provide this innovative injection to patients suffering from knee osteoarthritis.

Similarly, various clinics and other organizations are making an effort to create awareness among the population about osteoarthritis and available treatment options and promote patient engagement. For instance, the Spanish Rheumatology Society educates both people and healthcare professionals about osteoarthritis management. The Spanish Rheumatology Society and the Osteoarthritis Foundation International (OAFI) are working toward developing new lines of action in the field of research, training, and dissemination with the purpose of improving the joint health of osteoarthritis patients. Similarly, Clínic Barcelona helps raise awareness among the population about osteoarthritis and the various treatment options available, as well as educate them about its risk factors.

Bioventus Inc., SEIKAGAKU CORPORATION, Maxigen Biotech Inc., İstem Medical Inc., Sanofi SA, Ferring Pharmaceuticals, Fidia Pharma USA Inc., Biotech Healthcare Group, Bioteck S.p.A., and I+MED are among the leading companies profiled in the Europe intra-articular injection for osteoarticular infiltrations market report.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com